- Home
- XXI vs QURE Comparison
XXI vs QURE Comparison
Compare XXI & QURE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | XXI | QURE |
|---|---|---|
| Founded | 2025 | 1998 |
| Country | United States | Netherlands |
| Employees | N/A | 248 |
| Industry | Finance: Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.6B | 3.1B |
| IPO Year | 2026 | 2013 |
Fundamental Metrics
Financial Performance| Metric | XXI | QURE |
|---|---|---|
| Price | $6.75 | $23.37 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 12 |
| Target Price | N/A | ★ $68.25 |
| AVG Volume (30 Days) | 1.8M | ★ 1.9M |
| Earning Date | 11-11-2026 | 11-09-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 29.67 |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $13,107,000.00 |
| Revenue This Year | N/A | $55.91 |
| Revenue Next Year | N/A | $356.42 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $4.15 | $8.73 |
| 52 Week High | $11.49 | $71.50 |
Technical Indicators
Market Signals| Indicator | XXI | QURE |
|---|---|---|
| Relative Strength Index (RSI) | 60.86 | 19.51 |
| Support Level | $5.66 | $21.91 |
| Resistance Level | $7.45 | $27.66 |
| Average True Range (ATR) | 0.37 | 2.13 |
| MACD | 0.04 | -2.26 |
| Stochastic Oscillator | 80.42 | 10.03 |
Price Performance
Historical ComparisonAbout XXI Twenty One Capital Inc. Class A Common Stock
Twenty One Capital Inc is engaged in the Bitcoin-related business lines. It engages in two principal activities: actively accumulating Bitcoin and managing its Bitcoin holdings, and commencing development of educational materials and branded content intended to drive increased institutional and retail investor Bitcoin literacy.
About QURE uniQure N.V.
uniQure NV is a gene therapy company. It develops treatments and platforms for patients suffering from genetic and other devastating diseases. Its products and services are focused on hemophilia, Huntington's disease, and cardiovascular diseases. The company is focused on the development of the pipeline of gene therapies with the collaboration of Bristol Myers Squibb for cardiovascular diseases. Its program and pipeline involves: Huntington's Disease, Temporal Lobe Epilepsy (TLE), Fabry Disease, ALS (SOD1), Hemophilia B, Clinical Trials, and Research Programs.